Testing tumor samples for new drug targets in children and young adults
Part of Brain & nervous system, Cancer clinical trials.
This study looks at tumor samples from children and young adults with cancer that has come back or not gone away. The goal is to find specific markers on the tumor cells that could be targeted by new drugs called antibody-drug conjugates (ADCs), which deliver chemotherapy directly to cancer cells. This may help identify new treatment options for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with a solid tumor or a brain/spinal cord tumor before age 30.
- Your cancer has returned or did not go away with standard treatment.
- You have a tumor sample (tissue block or slides) available for testing, or you have had RNA sequencing done on your tumor.
- You are expected to live at least 12 weeks.
- For the retrospective part: you have previously received an antibody-drug conjugate (ADC) treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
This trial tests personalized cancer treatments for children and teens whose cancer has not responded to standard therapy. It uses information from precision medicine studies to match the right drug to each child's tumor.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This study collects and studies tissue or bone marrow samples from certain childhood tumors. The goal is to learn what’s going on inside the cancer (using molecular testing) to better understand the disease and how it may respond to treatment.
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Hear when a new CNS Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.